Inflammation and large arteries: Potential mechanisms for inflammation-induced arterial stiffness

Artery Research

Volumn 6, Issue 2, 2012, Pages 59-64

  Mäki Petäjä, Kaisa M ^a   Wilkinson, Ian B ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Aortic stiffness; Inflammation; Rheumatoid arthritis

Indexed keywords

C REACTIVE PROTEIN; ELASTIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GELATINASE A; GELATINASE B; GLYCOSAMINOGLYCAN; INDUCIBLE NITRIC OXIDE SYNTHASE; MYELOPEROXIDASE; PROTEOGLYCAN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ALLOSTERISM; ANTIINFLAMMATORY ACTIVITY; ARTERIAL STIFFNESS; ARTERY CALCIFICATION; ARTERY DISEASE; BIOAVAILABILITY; BIOCHEMICAL COMPOSITION; CELL PROLIFERATION; CHRONIC INFLAMMATION; CORONARY ARTERY DISEASE; DOWN REGULATION; ENDOTHELIAL DYSFUNCTION; EXTRACELLULAR MATRIX; HUMAN; NONHUMAN; OSTEOBLAST; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN SECRETION; PROTEIN STABILITY; RHEUMATIC DISEASE; SHORT SURVEY; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE; VASCULITIS;

EID: 84860698868     PISSN: 18729312     EISSN: 18764401     Source Type: Journal    
DOI: 10.1016/j.artres.2012.03.002     Document Type: Short Survey

References (75)

1. Libby P. Inflammation in atherosclerosis. Nature 2002 December 19, 420:868-874.
2. Liuzzo G., Biasucci L.M., Gallimore J.R., Grillo R.L., Rebuzzi A.G., Pepys M.B., et al. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med 1994 August 18, 331:417-424.
3. Ridker P.M., Rifai N., Rose L., Buring J.E., Cook N.R. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002 November 14, 347:1557-1565.
4. Hingorani A.D., Cross J., Kharbanda R.K., Mullen M.J., Bhagat K., Taylor M., et al. Acute systemic inflammation impairs endothelium-dependent dilatation in humans. Circulation 2000 August 29, 102:994-999.
5. Yasmin, McEniery C.M., Wallace S., Mackenzie I.S., Cockcroft J.R., Wilkinson I.B. C-reactive protein is associated with arterial stiffness in apparently healthy individuals. Arterioscler Thromb Vasc Biol 2004 May, 24:969-974.
6. Laurent S., Cockcroft J., Van Bortel L., Boutouyrie P., Giannattasio C., Hayoz D., et al. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J 2006 November, 27:2588-2605.
7. Laurent S., Boutouyrie P., Asmar R., Gautier I., Laloux B., Guize L., et al. Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension 2001 May, 37:1236-1241.
8. Blacher J., Guerin A.P., Pannier B., Marchais S.J., Safar M.E., London G.M. Impact of aortic stiffness on survival in end-stage renal disease. Circulation 1999 May 11, 99:2434-2439.
9. Shoji T., Emoto M., Shinohara K., Kakiya R., Tsujimoto Y., Kishimoto H., et al. Diabetes mellitus, aortic stiffness, and cardiovascular mortality in end-stage renal disease. J Am Soc Nephrol 2001 October, 12:2117-2124.
10. Guerin A.P., Blacher J., Pannier B., Marchais S.J., Safar M.E., London G.M. Impact of aortic stiffness attenuation on survival of patients in end-stage renal failure. Circulation 2001 February 20, 103:987-992.
11. Blacher J., Asmar R., Djane S., London G.M., Safar M.E. Aortic pulse wave velocity as a marker of cardiovascular risk in hypertensive patients. Hypertension 1999 May, 33:1111-1117.
12. Williams B., Lacy P.S., Thom S.M., Cruickshank K., Stanton A., Collier D., et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006 March 7, 113:1213-1225.
13. Boutouyrie P., Tropeano A.I., Asmar R., Gautier I., Benetos A., Lacolley P., et al. Aortic stiffness is an independent predictor of primary coronary events in hypertensive patients: a longitudinal study. Hypertension 2002 January, 39:10-15.
14. Laurent S., Katsahian S., Fassot C., Tropeano A.I., Gautier I., Laloux B., et al. Aortic stiffness is an independent predictor of fatal stroke in essential hypertension. Stroke 2003 May, 34:1203-1206.
15. Cruickshank K., Riste L., Anderson S.G., Wright J.S., Dunn G., Gosling R.G. Aortic pulse-wave velocity and its relationship to mortality in diabetes and glucose intolerance: an integrated index of vascular function?. Circulation 2002 October 15, 106:2085-2090.
16. Meaume S., Benetos A., Henry O.F., Rudnichi A., Safar M.E. Aortic pulse wave velocity predicts cardiovascular mortality in subjects >70 years of age. Arterioscler Thromb Vasc Biol 2001 December, 21:2046-2050.
17. Shokawa T., Imazu M., Yamamoto H., Toyofuku M., Tasaki N., Okimoto T., et al. Pulse wave velocity predicts cardiovascular mortality: findings from the Hawaii-Los Angeles-Hiroshima study. Circ J 2005 March, 69:259-264.
18. Willum-Hansen T., Staessen J.A., Torp-Pedersen C., Rasmussen S., Thijs L., Ibsen H., et al. Prognostic value of aortic pulse wave velocity as index of arterial stiffness in the general population. Circulation 2006 February 7, 113:664-670.
19. Mattace-Raso F.U., van der Cammen T.J., Hofman A., van Popele N.M., Bos M.L., Schalekamp M.A., et al. Arterial stiffness and risk of coronary heart disease and stroke: the Rotterdam Study. Circulation 2006 February 7, 113:657-663.
20. Vlachopoulos C., Aznaouridis K., Stefanadis C. Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis. J Am Coll Cardiol 2010 March 30, 55:1318-1327.
21. Wolfe F., Mitchell D.M., Sibley J.T., Fries J.F., Bloch D.A., Williams C.A., et al. The mortality of rheumatoid arthritis. Arthritis Rheum 1994 April, 37:481-494.
22. Van Doornum S., McColl G., Wicks I.P. Accelerated atherosclerosis: an extraarticular feature of rheumatoid arthritis?. Arthritis Rheum 2002 April, 46:862-873.
23. del Rincon I.D., Williams K., Stern M.P., Freeman G.L., Escalante A. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 2001 December, 44:2737-2745.
24. Symmons D.P., Jones M.A., Scott D.L., Prior P. Longterm mortality outcome in patients with rheumatoid arthritis: early presenters continue to do well. J Rheumatol 1998 June, 25:1072-1077.
25. Pasceri V., Yeh E.T. A tale of two diseases: atherosclerosis and rheumatoid arthritis. Circulation 1999 November 23, 100:2124-2126.
26. Maki-Petaja K.M., Hall F.C., Booth A.D., Wallace S.M., Yasmin, Bearcroft P.W., Harish S., et al. Rheumatoid arthritis is associated with increased aortic pulse-wave velocity, which is reduced by anti-tumor necrosis factor-alpha therapy. Circulation 2006 September 12, 114:1185-1192.
27. Van Doornum S., McColl G., Jenkins A., Green D.J., Wicks I.P. Screening for atherosclerosis in patients with rheumatoid arthritis: comparison of two in vivo tests of vascular function. Arthritis Rheum 2003 January, 48:72-80.
28. Booth A.D., Wallace S., McEniery C.M., Yasmin, Brown J., Jayne D.R., Wilkinson I.B. Inflammation and arterial stiffness in systemic vasculitis: a model of vascular inflammation. Arthritis Rheum 2004 February, 50:581-588.
29. Wallace S.M., Maki-Petaja K.M., Cheriyan J., Davidson E.H., Cherry L., McEniery C.M., et al. Simvastatin prevents inflammation-induced aortic stiffening and endothelial dysfunction. Br J Clin Pharmacol 2010 December, 70:799-806.
30. Angel K., Provan S.A., Gulseth H.L., Mowinckel P., Kvien T.K., Atar D. Tumor necrosis factor-alpha antagonists improve aortic stiffness in patients with inflammatory arthropathies: a controlled study. Hypertension 2010 February, 55:333-338.
31. Maki-Petaja K.M., Booth A.D., Hall F.C., Wallace S.M., Brown J., McEniery C.M., et al. Ezetimibe and simvastatin reduce inflammation, disease activity, and aortic stiffness and improve endothelial function in rheumatoid arthritis. J Am Coll Cardiol 2007 August 28, 50:852-858.
32. Bergholm R., Leirisalo-Repo M., Vehkavaara S., Makimattila S., Taskinen M.R., Yki-Jarvinen H. Impaired responsiveness to NO in newly diagnosed patients with rheumatoid arthritis. Arterioscler Thromb Vasc Biol 2002 October 1, 22:1637-1641.
33. Cleland S.J., Sattar N., Petrie J.R., Forouhi N.G., Elliott H.L., Connell J.M. Endothelial dysfunction as a possible link between C-reactive protein levels and cardiovascular disease. Clin Sci (Lond) 2000 May, 98:531-535.
34. Yki-Jarvinen H., Bergholm R., Leirisalo-Repo M. Increased inflammatory activity parallels increased basal nitric oxide production and blunted response to nitric oxide in vivo in rheumatoid arthritis. Ann Rheum Dis 2003 July, 62:630-634.
35. Gunnett C.A., Lund D.D., McDowell A.K., Faraci F.M., Heistad D.D. Mechanisms of inducible nitric oxide synthase-mediated vascular dysfunction. Arterioscler Thromb Vasc Biol 2005 August, 25:1617-1622.
36. Venugopal S.K., Devaraj S., Yuhanna I., Shaul P., Jialal I. Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells. Circulation 2002 September 17, 106:1439-1441.
37. Fichtlscherer S., Breuer S., Schachinger V., Dimmeler S., Zeiher A.M. C-reactive protein levels determine systemic nitric oxide bioavailability in patients with coronary artery disease. Eur Heart J 2004 August, 25:1412-1418.
38. Xu J., Xie Z., Reece R., Pimental D., Zou M.H. Uncoupling of endothelial nitric oxidase synthase by hypochlorous acid: role of NAD(P)H oxidase-derived superoxide and peroxynitrite. Arterioscler Thromb Vasc Biol 2006 December, 26:2688-2695.
39. Rabelink T.J., Luscher T.F. Endothelial nitric oxide synthase: host defense enzyme of the endothelium?. Arterioscler Thromb Vasc Biol 2006 February, 26:267-271.
40. Laursen J.B., Somers M., Kurz S., McCann L., Warnholtz A., Freeman B.A., et al. Endothelial regulation of vasomotion in apoE-deficient mice: implications for interactions between peroxynitrite and tetrahydrobiopterin. Circulation 2001 March 6, 103:1282-1288.
41. Kuzkaya N., Weissmann N., Harrison D.G., Dikalov S. Interactions of peroxynitrite, tetrahydrobiopterin, ascorbic acid, and thiols: implications for uncoupling endothelial nitric-oxide synthase. J Biol Chem 2003 June 20, 278:22,546-22,554.
42. Cosentino F., Katusic Z.S. Tetrahydrobiopterin and dysfunction of endothelial nitric oxide synthase in coronary arteries. Circulation 1995 January 1, 91:139-144.
43. Kinoshita H., Tsutsui M., Milstien S., Katusic Z.S. Tetrahydrobiopterin, nitric oxide and regulation of cerebral arterial tone. Prog Neurobiol 1997 July, 52:295-302.
44. Vasquez-Vivar J., Kalyanaraman B., Martasek P., Hogg N., Masters B.S., Karoui H., et al. Superoxide generation by endothelial nitric oxide synthase: the influence of cofactors. Proc Natl Acad Sci U S A 1998 August 4, 95:9220-9225.
45. Wallberg-Jonsson S., Cvetkovic J.T., Sundqvist K.G., Lefvert A.K., Rantapaa-Dahlqvist S. Activation of the immune system and inflammatory activity in relation to markers of atherothrombotic disease and atherosclerosis in rheumatoid arthritis. J Rheumatol 2002 May, 29:875-882.
46. Savage C.O., Pottinger B.E., Gaskin G., Pusey C.D., Pearson J.D. Autoantibodies developing to myeloperoxidase and proteinase 3 in systemic vasculitis stimulate neutrophil cytotoxicity toward cultured endothelial cells. Am J Pathol 1992 August, 141:335-342.
47. Morel D.W., Hessler J.R., Chisolm G.M. Low density lipoprotein cytotoxicity induced by free radical peroxidation of lipid. J Lipid Res 1983 August, 24:1070-1076.
48. Wallace S.M., Yasmin, McEniery C.M., Maki-Petaja K.M., Booth A.D., Cockcroft J.R., Wilkinson I.B. Isolated systolic hypertension is characterized by increased aortic stiffness and endothelial dysfunction. Hypertension 2007 July, 50:228-233.
49. Wilkinson I.B., Qasem A., McEniery C.M., Webb D.J., Avolio A.P., Cockcroft J.R. Nitric oxide regulates local arterial distensibility in vivo. Circulation 2002 January 15, 105:213-217.
50. Schmitt M., Avolio A., Qasem A., McEniery C.M., Butlin M., Wilkinson I.B., et al. Basal NO locally modulates human iliac artery function in vivo. Hypertension 2005 July, 46:227-231.
51. Montero I., Orbe J., Varo N., Beloqui O., Monreal J.I., Rodriguez J.A., et al. C-reactive protein induces matrix metalloproteinase-1 and -10 in human endothelial cells: implications for clinical and subclinical atherosclerosis. J Am Coll Cardiol 2006 April 4, 47:1369-1378.
52. Yasmin, Wallace S., McEniery C.M., Dakham Z., Pusalkar P., Maki-Petaja K., Ashby M.J., et al. Matrix metalloproteinase-9 (MMP-9), MMP-2, and serum elastase activity are associated with systolic hypertension and arterial stiffness. Arterioscler Thromb Vasc Biol 2005 February, 25:372.
53. Vlachopoulos C., Aznaouridis K., Dima I., Ioakeimidis N., Vasiliadou C., Zervoudaki A., et al. Negative association between serum levels of matrix metalloproteinases-2 and -9 and aortic stiffness in healthy adults. Int J Cardiol 2007 November 30, 122:232-238.
54. Yasmin, McEniery C.M., O'Shaughnessy K.M., Harnett P., Arshad A., Wallace S., Maki-Petaja K., et al. Variation in the human matrix metalloproteinase-9 gene is associated with arterial stiffness in healthy individuals. Arterioscler Thromb Vasc Biol 2006 August, 26:1799-1805.
55. Martyn C.N., Greenwald S.E. Impaired synthesis of elastin in walls of aorta and large conduit arteries during early development as an initiating event in pathogenesis of systemic hypertension. Lancet 1997 September 27, 350:953-955.
56. Moe S.M., Chen N.X. Inflammation and vascular calcification. Blood Purif 2005, 23:64-71.
57. Floege J., Ketteler M. Vascular calcification in patients with end-stage renal disease. Nephrol Dial Transplant 2004 August, 19(Suppl. 5):V59-V66.
58. Ford M.L., Tomlinson L.A., Smith E.R., Rajkumar C., Holt S.G. Fetuin-A is an independent determinant of change of aortic stiffness over 1 year in non-diabetic patients with CKD stages 3 and 4. Nephrol Dial Transplant 2010 June, 25:1853-1858.
59. Shroff R.C., Shah V., Hiorns M.P., Schoppet M., Hofbauer L.C., Hawa G., et al. The circulating calcification inhibitors, fetuin-A and osteoprotegerin, but not matrix Gla protein, are associated with vascular stiffness and calcification in children on dialysis. Nephrol Dial Transplant 2008 October, 23:3263-3271.
60. Dzau V.J., Braun-Dullaeus R.C., Sedding D.G. Vascular proliferation and atherosclerosis: new perspectives and therapeutic strategies. Nat Med 2002 November, 8:1249-1256.
61. Raines E.W. The extracellular matrix can regulate vascular cell migration, proliferation, and survival: relationships to vascular disease. Int J Exp Pathol 2000 June, 81:173-182.
62. Jacob M.P. Extracellular matrix remodeling and matrix metalloproteinases in the vascular wall during aging and in pathological conditions. Biomed Pharmacother 2003 July, 57:195-202.
63. Kaji T., Hiraga S., Yamamoto C., Sakamoto M., Nakashima Y., Sueishi K., et al. Tumor necrosis factor alpha-induced alteration of glycosaminoglycans in cultured vascular smooth-muscle cells. Biochim Biophys Acta 1993 March 10, 1176:20-26.
64. Toole B.P., Wight T.N., Tammi M.I. Hyaluronan-cell interactions in cancer and vascular disease. J Biol Chem 2002 February 15, 277:4593-4596.
65. Chai S., Chai Q., Danielsen C.C., Hjorth P., Nyengaard J.R., Ledet T., et al. Overexpression of hyaluronan in the tunica media promotes the development of atherosclerosis. Circ Res 2005 March 18, 96:583-591.
66. Li D., Fayad Z.A., Bluemke D.A. Can contrast-enhanced cardiac magnetic resonance assess inflammation of the coronary wall?. JACC Cardiovasc Imaging 2009 May, 2:589-591.
67. Hofmann L.V., Liddell R.P., Eng J., Wasserman B.A., Arepally A., Lee D.S., et al. Human peripheral arteries: feasibility of transvenous intravascular MR imaging of the arterial wall. Radiology 2005 May, 235:617-622.
68. Ng W.F., Fantin F., Ng C., Dockery F., Schiff R., Davies K.A., et al. Takayasu's arteritis: a cause of prolonged arterial stiffness. Rheumatology (Oxford) 2006 June, 45:741-745.
69. Yokoyama H., Kawasaki M., Ito Y., Minatoguchi S., Fujiwara H. Effects of fluvastatin on the carotid arterial media as assessed by integrated backscatter ultrasound compared with pulse-wave velocity. J Am Coll Cardiol 2005 December 6, 46:2031-2037.
70. Senzaki H., Chen C.H., Ishido H., Masutani S., Matsunaga T., Taketazu M., et al. Arterial hemodynamics in patients after Kawasaki disease. Circulation 2005 April 26, 111:2119-2125.
71. Cheung Y.F., Ho M.H., Tam S.C., Yung T.C. Increased high sensitivity C reactive protein concentrations and increased arterial stiffness in children with a history of Kawasaki disease. Heart 2004 November, 90:1281-1285.
72. Rheumatoid vasculitis 2007, Johns Hopkins Vasculitis Centre, Ref type: internet communication. http://vasculitis.med.jhu.edu/types/rheumatoid.html.
73. Watts R.A., Carruthers D.M., Symmons D.P., Scott D.G. The incidence of rheumatoid vasculitis in the Norwich Health Authority. Br J Rheumatol 1994 September, 33:832-833.
74. Gravallese E.M., Corson J.M., Coblyn J.S., Pinkus G.S., Weinblatt M.E. Rheumatoid aortitis: a rarely recognized but clinically significant entity. Medicine (Baltimore) 1989 March, 68:95-106.
75. Hollan I., Prayson R., Saatvedt K., Almdahl S.M., Nossent H.C., Mikkelsen K., et al. Inflammatory cell infiltrates in vessels with different susceptibility to atherosclerosis in rheumatic and non-rheumatic patients: a controlled study of biopsy specimens obtained at coronary artery surgery. Circ J 2008 December, 72:1986-1992.